Moderate TSH suppression may be better for patients with thyroid cancer

the ONA take:

According to a new study published online ahead of print in the journal Thyroid, researchers have found that moderate thyroid-stimulating hormone (TSH) suppression may be as beneficial as high suppression of the hormone responsible for driving thyroid cancer.


Higher TSH levels are associated with higher rates of thyroid cancer recurrence, but extreme suppression of TSH is linked with increased adverse events, such as arrhythmias and osteoporosis.

For the 30-year study, researchers analyzed data from 4,941 patients with thyroid cancer. Results showed that extreme TSH suppression offered no additional survival benefit compared with moderate TSH suppression in patients with high-risk disease. Moreover, researchers found that mild TSH suppression was beneficial for patients with low-risk thyroid cancer.

The findings suggest that further research is warranted to prospectively evaluate extreme TSH suppression versus moderate suppression in patients with high-risk thyroid cancer.

Breast cancer survivors may have increased risk of thyroid cancer
Moderate TSH suppression may be as beneficial as high suppression of the hormone responsible for driving the disease.
A study of long-term thyroid cancer outcomes shows, among other findings, that moderate suppression of TSH, which drives the disease, may be as beneficial as more extreme hormone suppression.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs